MRD-negative conversion with daratumumab monotherapy in newly diagnosed multiple myeloma patients in ≥VGPR/MRD-positive after first-line therapy: Final analysis of the open-label, single-arm multicent
4 hours ago
- #daratumumab
- #MRD-negative conversion
- #multiple myeloma
- Daratumumab monotherapy was evaluated in newly diagnosed multiple myeloma patients achieving ≥VGPR but remaining MRD-positive after first-line therapy.
- The primary endpoint at 6 months showed MRD-negative conversion in 30% (15/50) of patients; by 24 months, 22% (11/50) remained MRD-negative.
- Median progression-free survival was 45 months, with overall survival not reached; achieving MRD negativity significantly improved PFS (61 vs. 26 months, p=0.0009).
- At a median follow-up of 50 months, 58% of patients relapsed, but 21 patients did not progress and 4 relapsed patients remained in response without further treatment.